Get the Stockscreener App
9.84
2.77%
-0.28
Septerna Inc stock is traded at $9.84, with a volume of 2.32M.
It is down -2.77% in the last 24 hours and up +64.27% over the past month.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
See More
Previous Close:
$10.12
Open:
$10.57
24h Volume:
2.32M
Relative Volume:
2.06
Market Cap:
$433.94M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+47.09%
1M Performance:
+64.27%
6M Performance:
-56.32%
1Y Performance:
+0.00%
1-Day Range:
$9.52
$10.87
1-Week Range:
$6.44
$11.36
52-Week Range:
$4.17
$28.99
Septerna Inc Stock (SEPN) Company Profile
Name
Septerna Inc
Sector
Industry
Phone
650-338-3533
Address
250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO
Compare SEPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
9.84 | 297.81M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-19-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-19-24 | Initiated | JP Morgan | Overweight |
| Nov-19-24 | Initiated | TD Cowen | Buy |
| Nov-19-24 | Initiated | Wells Fargo | Overweight |
Septerna Inc Stock (SEPN) Latest News
Septerna First Quarter 2025 Earnings: US$0.49 loss per share (vs US$6.35 loss in 1Q 2024) - simplywall.st
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments - MSN
Septerna: Novo's Investment In Incretin Program IntriguesOne For The Watchlist - Seeking Alpha
Where Septerna Stands With Analysts - Benzinga
Septerna: Deal With Novo Nordisk Is A Game Changer, While It Still Trades Well Below Net Cash - Seeking Alpha
Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight By Investing.com - Investing.com Nigeria
Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight - Investing.com
Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership - PMLiVE
Septerna price target raised to $18 from $11 at Wells Fargo - TipRanks
Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills - MSN
Septerna, Inc.: Strategic Partnerships and Promising Pipeline Drive Buy Rating - TipRanks
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna - MSN
Septerna reports Q1 EPS (49c), consensus (45c) - TipRanks
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results - The Manila Times
Septerna Lands Massive $2.2B Novo Nordisk Partnership to Revolutionize Oral Diabetes and Obesity Treatments - Stock Titan
Novo Nordisk, Septerna in $2.2 Billion Obesity Pill Partner Deal - MSN
Novo Nordisk Inks $2.2B Deal With Septerna: Retail’s Thrilled - MSN
Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs - Contract Pharma
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk - MSN
ETFs to Capitalize on the Novo Nordisk-Septerna Deal - Yahoo Finance
Is It Time to Buy the Dip in Novo Nordisk Stock? - Investing.com
Novo Nordisk, Septerna collaborate on developing GPCR therapies - World Pharmaceutical Frontiers
Novo Nordisk Partners with Septerna for New Obesity Drug Development - GuruFocus
Novo Nordisk, Septerna Ink Up To $2.2B Obesity Drug Deal - Law360
Novo Nordisk Looks To Septerna For Oral Obesity Options - insights.citeline.com
Septerna joins a $2.2B obesity deal with Novo - BioWorld MedTech
Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing - Investor's Business Daily
Novo Nordisk, Septerna Agree $2.2 Billion Obesity Pill Deal - MSN
eToro's Nasdaq debut, Exelixis outlook, Septerna–Novo deal - Yahoo Finance
Money Movers: HIT, SEPN, ALUR, LUCY, PRSO – Biotech, Healthcare, AI & Weight Loss Innovators Lead Momentum Surge – More Stocks Inside | FinancialContent - FinancialContent
Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies - Pharmaceutical Technology
This biotech’s stock rockets on oral obesity drug partnership with Wegovy parent - MSN
Septerna Stock Spikes on Novo Nordisk Obesity Drug Deal - Wall Street Pit
Novo Doubles Down on Oral Obesity Meds With Septerna Deal Worth up to $2.4B - BioSpace
Peninsula biotech Septerna lands deal for oral GLP-1 weight-loss drugs, stock zooms higher - The Business Journals
Novo Nordisk (NVO) Partners with Septerna to Develop Obesity and Diabetes Drugs - GuruFocus
Novo Nordisk Rises on Weight-Loss Deal. Septerna Stock Gains Even More. - Barron's
Septerna and Novo Nordisk to collaborate on oral obesity and other cardiometabolic diseases - The Pharma Letter
Novo Nordisk in pact with Septerna for oral obesity drugs - MSN
Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs - Benzinga
First patient treated with prime editing - statnews.com
Novo Nordisk, Septerna sign $2.2B deal to develop weight-loss pill - Yahoo Finance
Novo Nordisk, Septerna in $2.2 Billion Obesity Pill Partner Deal (SEPN) - Bloomberg
$2.2 billion deal: Septerna and Novo Nordisk collaborate on obesity, cardiometabolic diseases - PharmaLive
novo-nordisk-partners-with-septerna-on-obesity-drugs - baha.com
Novo makes fresh obesity play with $2.2bn Septerna deal - Pharmaphorum
Novo Nordisk partners with Septerna on obesity drugs - breakingthenews.net
Novo to work with Septerna in hunt for oral obesity drugs - Yahoo Finance
Septerna jumps 60% after Novo Nordisk partnership to develop oral obesity drugs - TradingView
Septerna stock pops on partnership with Novo Nordisk to develop obesity therapies - Proactive financial news
Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases - marketscreener.com
Septerna Inc Stock (SEPN) Financials Data
There is no financial data for Septerna Inc (SEPN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Septerna Inc Stock (SEPN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Finer Jeffrey | CEO and President |
Apr 03 '25 |
Option Exercise |
2.76 |
5,000 |
13,800 |
826,907 |
| Ezekowitz Alan | Director |
Mar 07 '25 |
Buy |
6.93 |
13,319 |
92,270 |
117,420 |
| Ezekowitz Alan | Director |
Mar 06 '25 |
Buy |
6.00 |
41,355 |
248,130 |
104,101 |
| Ezekowitz Alan | Director |
Mar 05 '25 |
Buy |
5.82 |
37,835 |
220,260 |
62,746 |
| Ezekowitz Alan | Director |
Mar 04 '25 |
Buy |
6.35 |
7,491 |
47,544 |
24,911 |
| Finer Jeffrey | CEO and President |
Feb 25 '25 |
Buy |
5.68 |
10,000 |
56,765 |
764,907 |
| Finer Jeffrey | CEO and President |
Feb 26 '25 |
Buy |
5.70 |
4,000 |
22,796 |
768,907 |
| Finer Jeffrey | CEO and President |
Feb 27 '25 |
Buy |
5.80 |
3,000 |
17,400 |
771,907 |
| Labrucherie Gil M | Chief Financial Officer |
Feb 25 '25 |
Buy |
5.59 |
6,282 |
35,116 |
36,282 |
| Labrucherie Gil M | Chief Financial Officer |
Feb 27 '25 |
Buy |
5.85 |
3,718 |
21,750 |
40,000 |
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):